Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL.

NCT04508842 is registered in ClinicalTrials.gov with Hebei Yanda Ludaopei Hospital as lead sponsor.

NCT NCT04508842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL.
Lead sponsor
Hebei Yanda Ludaopei Hospital
Phase
Phase 1
Overall status
Terminated
Start date
October 10, 2020
Completion date
May 1, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory and relapsed b cell acute leukemia